Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Korean Urological Oncology Society 2024-03-01
Cyfres:	Journal of Urologic Oncology
Pynciau:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
Mynediad Ar-lein:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Eitemau Tebyg

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
gan: Huang JT, et al.
Cyhoeddwyd: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
gan: Pan X, et al.
Cyhoeddwyd: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
gan: Fei Yang, et al.
Cyhoeddwyd: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
gan: Hongyu Pan, et al.
Cyhoeddwyd: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
gan: A. Yu. Goryainova, et al.
Cyhoeddwyd: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
gan: Gao B, et al.
Cyhoeddwyd: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
gan: Ning Luo, et al.
Cyhoeddwyd: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
gan: Shannon E. Kelly, et al.
Cyhoeddwyd: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
gan: Guosheng Yuan, et al.
Cyhoeddwyd: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
gan: Sang Youn Hwang, et al.
Cyhoeddwyd: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
gan: Christopher Kwok, et al.
Cyhoeddwyd: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
gan: Junfeng Bu, et al.
Cyhoeddwyd: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
gan: Karam Khaddour, et al.
Cyhoeddwyd: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
gan: Yiwan Guo, et al.
Cyhoeddwyd: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
gan: David O’Reilly, et al.
Cyhoeddwyd: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
gan: Yifan Zhang, et al.
Cyhoeddwyd: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
gan: Shasha Sun, et al.
Cyhoeddwyd: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
gan: Emmy D. G. Fleuren, et al.
Cyhoeddwyd: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
gan: Jian Wang, et al.
Cyhoeddwyd: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
gan: Changjie Du, et al.
Cyhoeddwyd: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
gan: Renguo Guan, et al.
Cyhoeddwyd: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
gan: Yuhang Chen, et al.
Cyhoeddwyd: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
gan: Qiao Ke, et al.
Cyhoeddwyd: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
gan: Ling Peng, et al.
Cyhoeddwyd: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
gan: Yue Chen, et al.
Cyhoeddwyd: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
gan: Halil Ibrahim Onder, et al.
Cyhoeddwyd: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
gan: Ichiro Yamauchi, et al.
Cyhoeddwyd: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
gan: Daniela R. Montagna, et al.
Cyhoeddwyd: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
gan: Pottayil G. Sasikumar, et al.
Cyhoeddwyd: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
gan: Ryo Ariyasu, MD, et al.
Cyhoeddwyd: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
gan: Yi-fan Chen, et al.
Cyhoeddwyd: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
gan: Kexue Deng, et al.
Cyhoeddwyd: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
gan: Jingyang Su, et al.
Cyhoeddwyd: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
gan: Eva Zhang, et al.
Cyhoeddwyd: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
gan: CHEN Shuangqing, et al.
Cyhoeddwyd: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
gan: Qi Zhu, et al.
Cyhoeddwyd: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
gan: Hanping Wang, et al.
Cyhoeddwyd: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
gan: Yuanquan Yang, et al.
Cyhoeddwyd: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
gan: João Queirós Coelho, et al.
Cyhoeddwyd: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
gan: Hor-Yue Tan, et al.
Cyhoeddwyd: (2018-02-01)